Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis
- PMID: 9656314
- DOI: 10.2466/pms.1998.86.3.1099
Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis
Abstract
The effects of interferon Beta 1-b (Betaseron) on verbal memory functioning was examined in 167 patients with relapsing-remitting multiple sclerosis and 112 matched normal controls. Subjects were administered 10 verbal memory tests from the Memory Assessment Scales and the Verbal subtests from the Wechsler Adult Intelligence Scale. Analysis showed subjects treated with Betaseron (n = 73) did not perform significantly better on measures of verbal memory or verbal ability than subjects not receiving the drug (n = 94), although the mean performance of treated subjects was higher across all verbal memory tests. Both groups of patients performed significantly worse on verbal memory subtests measuring list acquisition, delayed list recall, delayed cued recall, and the immediate and delayed recall of names and faces than control subjects. Although patients had lower performance scores across all memory tests than the control subjects, their scores were not within the impaired range. These results do not permit a clear conclusion about the effects of Betaseron on verbal memory for any effect is probably obscured by the relatively preserved cognitive functioning of this outpatient sample.
Similar articles
-
Assessment of memory in multiple sclerosis patients using the Memory Assessment Scale.Percept Mot Skills. 1998 Jun;86(3 Pt 1):987-98. doi: 10.2466/pms.1998.86.3.987. Percept Mot Skills. 1998. PMID: 9656299
-
The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.Mult Scler. 2013 Nov;19(13):1765-72. doi: 10.1177/1352458513485981. Epub 2013 May 7. Mult Scler. 2013. PMID: 23652214
-
A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis.Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):32-44. Neuropsychiatry Neuropsychol Behav Neurol. 2001. PMID: 11234907
-
Treatment of multiple sclerosis with interferon beta 1b.Baillieres Clin Neurol. 1997 Oct;6(3):467-80. Baillieres Clin Neurol. 1997. PMID: 10101584 Review.
-
[The role of interferon beta in the treatment of multiple sclerosis].Rev Med Brux. 1999 Sep;20(4):A264-7. Rev Med Brux. 1999. PMID: 10523902 Review. French.
Cited by
-
Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.Mol Diagn Ther. 2009;13(4):225-44. doi: 10.1007/BF03256329. Mol Diagn Ther. 2009. PMID: 19712003 Review.
-
Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.J Neurol. 2007 May;254 Suppl 2:II69-72. doi: 10.1007/s00415-007-2016-3. J Neurol. 2007. PMID: 17503133 Review.
-
Cognitive impairments in multiple sclerosis: a review.Am J Alzheimers Dis Other Demen. 2002 Jan-Feb;17(1):23-9. doi: 10.1177/153331750201700104. Am J Alzheimers Dis Other Demen. 2002. PMID: 11831417 Free PMC article. Review.
-
[Cognitive dysfunctions in multiple sclerosis patients].Nervenarzt. 2005 Aug;76(8):943-4, 946-8, 951-3. doi: 10.1007/s00115-005-1901-1. Nervenarzt. 2005. PMID: 15765229 Review. German.
-
Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.CNS Drugs. 2020 Jun;34(6):599-628. doi: 10.1007/s40263-020-00734-4. CNS Drugs. 2020. PMID: 32361940 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical